• View Reports By Topic >>
  • A-B »

    • A
      	•Adderall® •Adolescents •ADHD Stimulant Medications •ADSS (Alcohol & Drug Services Study) •Adults •Adverse Reactions •Alcohol •Alcohol dependence •Alcohol problems •Alcohol treatment •Amphetamines •Analgesics
      B
      	•Benzodiazepines •Binge drinking •Buprenorphine

  • C »

    • C
      	•Children and families •Church/Faith-based activities •Cigarettes, Cigars (see tobacco) •Cities / urban areas •Cocaine/crack cocaine •Comorbidity/Co-occurring disorders •Costs of treatment •Cough medicine •Criminal justice system

  • D »

    • D

      •DASIS (Drug Abuse Services Information System) •DAWN (Drug Abuse Warning Network) •Depression •Detox/Detoxification •Dextromethorphan® • Driving under the Influence; Driving While Intoxicated (DUI/DWI) •Drug Services Research Survey (DSRS) •Drugs •Drug Dependence •Drug Problems •Drug Treatment •Drug brand / generic names •Drug names: Pronunciation •Drug Services Research Survey •DSRS (Drug Services Research Survey) •DUI/DWI

  • E-H »

    • E
      	•Ecstasy (MDMA) •Elderly/Older adults •Emergency Department visits
      F
      	•Females •Flunitrazapam (see sedatives)
      G
      	•Gender •GHB (Gamma Hydroxy Butyrate) •Generic/brand drug names
      H
      	•Hallucinogens •Hashish (see Marijuana) •Health insurance •Heavy drinking •Heroin •Hydrocodone (see analgesics)

  • I-L »

    • I
      	•Inhalants •Inhalation drug use •Inpatient treatment •Injection drug use •Insurance
      J
      K
      	•Ketamine
      L	•LAAM •Licensing regulations and drinking •LSD

  • M-N »

    • M
      	•Marijuana /hashish •MDMA (Ecstasy) •Mental health •Methadone •Methamphetamine
      N
      	•Nicotine •Nonmedical use of prescription drugs •Non response report •NSDUH/NHSDA •N-SSATS

  • O-Q »

    • O
      	•Older Adults •Opiates •Outpatient treatment •Over-the-Counter drugs •Oxycodone •Oxycontin®
      P
      	•Pain relievers •PCP •Perceived Risk •Peyote •Pregnant/recent mothers •Prescription drugs
      Q

  • R »

    • R
      	•Racial & ethnic groups: •African Americans •Alaskan Natives •American Indians •Asians •Blacks •Hispanics •Latinas/Latinos •Pacific Islanders •Whites/Caucasians •Regions •Residential treatment •Ritalin® •Rohypnol ® •Rural/urban areas

  • S »

    • S
      	•Salvia divinorum (see hallucinogens) •Sedatives •Special studies •Specific drugs •Speed/Amphetamine •SROS (Services Research Outcome Study) •State data •Stimulants •Substance Use •Sub State data •Suicide •Support

  • T-Z »

    • T
      	•TEDS • Tobacco (Cigarettes, cigars, smokeless tobacco) •Tranquilizers •Treatment Locator
      U
      	•Urban/rural areas
      V
      	•Veterans •Violence
      W
      	•Women
      X
      	•XTC (see Ecstasy/MDMA)
      Y
      	•Young Adults (18-25 years of age) •Youth (under 17 years of age)
      Z

The purpose of Strategic Initiative #7 is to realize an integrated data strategy and a national framework for quality improvement in behavioral health care that will inform policy, measure program impact, and lead to improved quality of services and outcomes for individuals, families, and communities